Alexion shares some blockbuster Soliris love with Ireland

Alexion Pharmaceuticals ($ALXN) plans to add 50 new jobs at its new supply chain outpost in Dublin, where the U.S. biotech powerhouse will house a variety of operations to provide customers abroad with its rare disease therapy Soliris. As The Irish Times reports, the company aims to begin shipping the therapy for rare blood disorders from the facility before the end of this year. Ireland, which has been recovering from an economic slowdown, has been hungry for new jobs. Item

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.

The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population.